钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展  

Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction

作　　者：郝潇[1] 赵美 王文静[1] 张飞飞[1] 刘惠良[1] 党懿[1] 李树仁[1] 齐晓勇[1] HAO Xiao;ZHAO Mei;WANG Wenjing;ZHANG Feifei;LIU Huiliang;DANG Yi;LI Shuren;QIXiaoyong(Hebei General Hospital,Shijiazhuang 050000,Hebei,China)

机构地区：[1]河北省人民医院,河北石家庄050000

出　　处：《中国临床药理学与治疗学》2023年第7期824-831,共8页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省2022年度医学科学研究课题计划(20220857)。

摘　　要：钠-葡萄糖共转运体2(SGLT2)抑制剂目前已在心力衰竭(合并/不合并糖尿病)治疗中有明确获益。心肌梗死后心室重构,导致心力衰竭发生和发展,最终导致死亡。心肌梗死患者应用SGLT2抑制剂的研究相对较少。本文目的在于综述心肌梗死前后应用SGLT2抑制剂的研究进展。SGLT2 inhibitors currently have clear benefits in the treatment of heart failure whether combined with diabetes or not.Ventricular remodeling after myocardial infarction leads to the occurrence and development of heart failure,and eventually leads to death.There are relatively few studies on SGLT2 inhibitors in patients with myocardial infarction.The purpose of this article is to review the research progress of SGLT2 inhibitors application before and after myocardial infarction.

关 键 词：急性心肌梗死 钠-葡萄糖共转运体2抑制剂 心室重构 心力衰竭 

分 类 号：R542.2[医药卫生—心血管疾病]